SONM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DNA X Inc (SONM) is not a good buy for a beginner investor with a long-term strategy. The company is facing significant financial challenges, including negative EPS, insufficient cash reserves, and insider selling activity. Technical indicators also suggest bearish trends, and there are no strong positive catalysts to justify an investment at this time.
The MACD is slightly positive, but the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The pre-market price of $3.08 is below the pivot level of $3.31, suggesting weakness. Key support levels are at $2.947 and $2.723, while resistance levels are at $3.673 and $3.897.
The company is focused on long-term growth through its trading business.
Insiders are selling heavily, with a 610.08% increase in selling activity over the last month. The company reported a GAAP EPS of -$11.00 for the fiscal year and insufficient cash reserves of $1.3 million for expansion. Gross margin dropped significantly by -60.24% YoY.
In 2025/Q3, revenue increased by 7.94% YoY to $16,214,000, and net income improved by 89.21% YoY to -$4,753,000. However, EPS remains deeply negative at -86.86, despite an 831.97% YoY improvement. Gross margin dropped to 11.2%, down -60.24% YoY, indicating declining profitability.
No recent analyst rating or price target data is available.
